



13 August 2019

ASX Announcement

## Race announces additional US Patent for Bisantrene

---

**13 August 2019: Race Oncology Limited ('Race')** is pleased to announce that it has secured a new patent on its cancer drug, Bisantrene, from the United States Patent and Trademarks Office (USPTO). This is Race's third patent granted on Bisantrene in the United States.

"The new US patent allows additional claims around the use of Bisantrene in combination with other drugs for treating cancer," said Race CEO Peter Molloy. "Given that most cancer treatments employ combination regimens, we believe these new claims significantly bolster the attractiveness of Bisantrene to commercial partners."

The new patent covers expanded uses of Bisantrene, in particular its use in combination with other cancer drugs to treat Acute Myeloid Leukaemia (AML) and breast cancer.

This includes the use of Bisantrene in combination with cytarabine, hypomethylating agents (for example, azacitidine and decitabine), checkpoint inhibitors and other targeted immune therapies, as well as other classes of cancer drugs.

The new patent is the result of a divisional application following on from one of the Race's previous Bisantrene patents granted in 2018 in the US (US9974774), which protected the use of Bisantrene in patients with refractory or relapsed cancers, including AML and related leukaemias, as well as breast cancer, lymphoma and other cancers. The latest patent expands Bisantrene's protected use to combination therapies.

- ENDS -

### **About Race Oncology (RAC: ASX)**

Race Oncology is a specialty pharmaceutical company whose business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is Bisantrene, a chemotherapy drug, which was the subject of more than 40 clinical studies during the 1980s and 1990s before the drug was abandoned. Bisantrene has compelling Phase II data in acute myeloid leukaemia (AML) and Race is seeking to gain US FDA approval for Bisantrene for AML under the accelerated 505(b)(2) regulatory pathway. Bisantrene is the subject of two recently granted US patents and a third allowed US patent. It has also been awarded US Orphan Drug designation and a 'Rare Paediatric Disease' (RPD) designation.

### **Media contact:**

Heidi Cuthbert, Multiplier

P: +61 411 272 366

E: heidi.cuthbert@multiplier.com.au